Latest Industry Insights

Explore the unique issues of rare disease trials and how “gene silencing” therapies could reshape the future for patients with H-ABC.

ELRIG Drug Discovery 2025 recognizes BubbleFect, a lipid-free cell delivery system that utilizes phase separation peptides for non-viral gene therapy delivery.

In this interview, we explore how single-cell technologies, automation and strategic partnerships are shaping the future of cancer immunotherapy.

Discover how one of the biggest biopharma acquisitions of 2025 aims to expand rare tumor therapies for hard-to-treat cancers like desmoid tumors.

In this article, we explore how AI, robotics and advanced software are transforming biopharma labs, the challenges of adopting these technologies and the vision for the “Lab of the Future.”

In this interview, Dr. Denise Teber, a scientific expert in molecular biology at Charles River Laboratories, discusses how ddPCR is being used to improve contamination risk management.

In this interview, Dr. Eleonora Juarez explains how Oxford Nanopore’s new Hereditary Cancer Panel could streamline testing, expand access and influence future best practices in hereditary cancer workflows.

In this interview, Dr. Freya Leech, a researcher at NanoFCM, discusses the current challenges and future prospects in nanoparticle drug delivery.

Explore how onshoring pharmaceutical manufacturing could reshape US drug production and boost supply chain resilience.

In this interview, Technology Networks spoke with Gene Mack, chief executive officer and president of Gain Therapeutics, to find out more about the company’s mission, its science and its vision for the future of neuroscience drug development.